What Okitask Treats: Main Uses and Benefits

Okitask provides symptomatic support that is relevant for conditions involving the acute onset of pain, inflammation, and fever. The medication is commonly used to help with minor aches and pain, is applied in addressing fever, and assists with easing discomfort across several body systems. It supports general comfort and functional stability.

The primary therapeutic benefit is applied in managing acute symptomatic episodes, particularly when symptoms cluster into patterns requiring supportive management. It is commonly used across conditions presenting with localized discomfort, such as minor musculoskeletal issues like sprains, strains, and lumbago; inflammatory symptoms in the throat, including pharyngitis and tonsillitis; and specific episodic pain states like headaches and primary dysmenorrhea.

“The medication is applied in scenarios where additional management of discomfort is required, helping patients cope more steadily with symptom fluctuations.”

Quick Fact: Symptomatic Support Domains Okitask is commonly used when symptoms of acute pain intensify, supporting relief across domains involving tissue injury, localized inflammatory states, and elevated body temperature, contributing to easing the overall symptom load.

Regulatory References

1. NIH MedlinePlus overview of Ketoprofen

Okitask is an authorized Non-Steroidal Anti-Inflammatory Drug (NSAID) available for use only by specific populations, as determined by regulatory authorities. The official labeling mandates strict exclusions for certain patient groups and pre-existing conditions.

Eligibility Scope

Category	Official Regulatory Status
Populations Allowed	Adults and adolescents aged 15 years and above (some jurisdictions specify 18 years and above).
Populations Contraindicated	Children and adolescents under 15 years of age.
Pregnancy/Lactation Status	Contraindicated during the third trimester of pregnancy and during lactation (breastfeeding).

Mandatory Exclusions (Contraindications)

The medicine must not be used by individuals with the following official contraindications, which are defined in the regulatory labeling:

• Hypersensitivity: A known history of allergic reactions (such as asthma, bronchospasm, or hives) to ketoprofen, acetylsalicylic acid, or other NSAIDs.
• Gastrointestinal Disease: Active peptic ulcer/haemorrhage, or a history of recurrent gastrointestinal bleeding, ulceration, or perforation [Source 1.1, 1.2, 1.4].
• Severe Organ Dysfunction: Diagnosed severe heart failure, severe renal insufficiency, or severe hepatic insufficiency.
• Excipient Restriction: Patients diagnosed with phenylketonuria (due to the excipient aspartame in some formulations).

Conditional Use

Use is restricted and requires careful consideration for elderly patients due to an increased risk of adverse reactions, particularly gastrointestinal events.

The official interaction profile for Okitask (Ketoprofen lysine salt) is defined by documented potential for synergistic adverse effects and interference with renal clearance pathways, as stated in government regulatory sources.

Contraindicated and Avoided Combinations

Co-administration with other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including high-dose salicylates, is avoided due to a documented synergistic risk of gastrointestinal ulcers and haemorrhage. The use of Okitask is contraindicated for the management of perioperative pain during coronary artery bypass graft (CABG) surgery. The simultaneous use with oral anticoagulants (such as Warfarin) or parenteral Heparins increases the risk of severe haemorrhage, attributed to the product’s effect on platelet function.

Interactions Affecting Exposure and Function

Co-administration with Lithium or high-dose Methotrexate is documented to elevate plasma levels of these medicines by inhibiting their renal clearance, thus increasing the risk of toxicity. Diuretics, ACE Inhibitors, and ARBs may have their efficacy diminished and present an increased risk of acute renal function deterioration. This renal risk is heightened in specific populations, including the elderly and patients who are volume-depleted. Administration with Anti-platelet Agents, SSRIs, or Oral Corticosteroids is noted to increase the additive risk of gastrointestinal bleeding. A mandatory timing restriction is required for Pemetrexed, where Okitask dosing must be interrupted for several days before and after treatment to manage exposure. Alcohol consumption is an avoided combination due to an elevated risk of GI bleeding.

The Pharmacodynamic Mechanism

The mechanism of action for Okitask is determined by its active molecule, ketoprofen, which functions as a reversible, non-selective inhibitor of the Cyclooxygenase (COX-1 and COX-2) enzymes. This binding blocks the enzymatic conversion of arachidonic acid into prostaglandins, lipid mediators involved in inflammation and nociception. This molecular action modifies early steps in the Arachidonic Acid Cascade, influencing subsequent systemic physiological outcomes. By limiting prostaglandin E2 (PGE2) synthesis, the mechanism directly reduces the sensitization of peripheral nociceptors and modulates PGE2-driven signaling in the hypothalamus . This alters signaling dynamics in the neural and humoral pathways associated with nociception and thermoregulation. The formulation utilizes the highly soluble lysine salt of ketoprofen, a factor which ensures the active molecule reaches its target enzymes sooner, facilitating the rapid onset of the inhibitory mechanism.

How to Use Okitask

The usage of Okitask (Ketoprofen lysine salt 25 mg granules) is governed by instructions that define a precise oral route, specific dosing limits, and strict duration constraints, ensuring standardized use for acute symptomatic relief.

---

Official Administration Protocol

The product is designated for oral administration as coated granules. For use, the contents of one sachet are to be placed directly onto the tongue and swallowed, where they dissolve with saliva. The medicine may be taken with or without water, though it is generally preferable to take the product on a full stomach.

---

Labeled Dosing and Scheduling

Administration is structured around an as-needed schedule for short-term symptomatic relief, not to exceed the established maximum limits.

Feature	Instruction / Rule
Single Dose (Adults ge 18 years)	1 sachet (25 mg Ketoprofen).
Maximum Daily Dose	3 sachets (75 mg Ketoprofen) in any 24-hour period.
Minimum Dose Interval	At least 4 hours must be observed between administrations.
Duration of Use	Strictly for short-term use only; medical consultation is required if symptoms persist or if needed for more than 10 days.

---

Population-Specific Use Rules

Specific dosage limits apply to certain groups. The medicine is not to be used in children and adolescents under the age of 18 years. For older adults, a reduced regimen of 1 sachet a day (25 mg total) is recommended.

Okitask: Recent Clinical Evidence

Summary of Research Findings

Okitask contains ketoprofen lysine salt, which is the lysine salt of the non-steroidal anti-inflammatory drug (NSAID) ketoprofen. Research has primarily focused on the drug’s effectiveness in managing acute, mild to moderate pain, consistent with its authorized use for conditions such as headache, toothache, menstrual pain (dysmenorrhea), and pain associated with cold and flu.

Studies examining the drug's oral granule formulation show that its salt form is associated with a more rapid absorption rate compared to the racemic drug, an observation consistent with the goal of achieving a quick onset of relief in acute pain settings. Randomized, placebo-controlled trials have been used to assess the drug's performance in standard models of acute pain, such as post-operative dental pain.

Efficacy and Speed of Effect

Clinical data from randomized trials indicate that the oral formulation is associated with measurable reductions in pain intensity over the study period when compared to a placebo. Specific findings related to the speed of effect, a secondary measure in some trials, have reported that most study participants experienced initial perceptible relief within 30 to 72 minutes following administration of the 25 mg dose.

Condition Studied	Study Design Focus	Key Assessment Measure
Acute Pain (e.g., Dental)	Single dose, placebo-controlled	Reduction in Pain Intensity (VAS)
Acute Musculoskeletal Pain	Comparison with other analgesics	Opioid-sparing effect; Time to relief

Safety and Special Groups

Research has explored the drug's safety and pharmacokinetic profile in various populations. Studies analyzing the elimination and absorption (pharmacokinetics) in older adults (over 65 years) generally did not report data supporting the need for dose changes based solely on age. The adverse events observed in clinical trials are largely consistent with those known for NSAIDs, primarily involving gastrointestinal issues. Further research is ongoing to characterize long-term outcomes and potential combination uses.

Common questions about Okitask (FAQ)

Q: What is Okitask used for?

Okitask is an NSAID (nonsteroidal anti-inflammatory drug) that is used in some clinical settings for the short-term, symptomatic treatment of occasional pain, such as headaches, muscle aches, or dental pain.

---

Q: How quickly does Okitask start working?

In clinical studies, the absorption of the active ingredient, ketoprofen, into the bloodstream has been observed to occur rapidly. A reduction in pain sensation may be experienced relatively quickly after administration.

---

Q: What type of active ingredient is in Okitask?

The active ingredient in Okitask is ketoprofen, which is part of the arylpropionic acid group of NSAIDs. It works by affecting the production of certain substances in the body that are involved in pain and inflammation.

---

Q: Is Okitask a different type of pain reliever than paracetamol (acetaminophen)?

Yes, Okitask (ketoprofen) is an NSAID, and its mechanism of action is different from that of paracetamol (acetaminophen). NSAIDs primarily function by inhibiting the synthesis of prostaglandins, which are key mediators of inflammation and pain.

How to Store and Dispose of Okitask (Ketoprofen Lysine Salt)

Okitask must be stored strictly according to regulatory labeling to maintain product stability.

Storage Conditions

Requirement	Official Rule
Temperature	Store at a temperature not exceeding 25 C and away from excessive heat.
Protection	Must be kept protected from light and moisture; do not freeze.
Packaging	Store in the original container and keep tightly closed.
Child Safety	Keep the medicine out of the sight and reach of children.

Shelf-Life and Disposal

The medicine must not be used after the expiry date shown on the carton, which is valid only if the product is stored correctly and the packaging is intact. Patients should consult a pharmacist or healthcare professional for instructions on how to properly dispose of unused or expired Okitask, adhering to local pharmaceutical waste handling guidelines.